Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-azacyclopeptide
- Development stage
- Preclinical
- Lead developer
- Bar-Ilan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
64Cu-azacyclopeptide is a copper-64 labeled cyclic peptide mimetic (specifically an azacyclo-D,L-α-peptide) developed as a positron emission tomography (PET) imaging tracer for the early diagnosis of Alzheimer's disease. The tracer is designed to cross the blood-brain barrier and selectively target and bind to soluble, low molecular weight amyloid-beta (Aβ) oligomers, which are early biomarkers of cognitive decline that accumulate prior to the formation of insoluble fibrils and plaques. By enabling the visualization and quantification of these early-stage oligomeric aggregates, 64Cu-azacyclopeptide offers potential for early-stage detection of Alzheimer's disease. It was co-developed and patented by researchers from the Université de Sherbrooke, Université de Montréal, and Bar-Ilan University.
- Other names
- 64Cu-Azacyclopeptide64Cu-labeled azacyclopeptidecopper-64 azacyclopeptidecopper64 azacyclopeptidecopper 64 azacyclopeptide
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on 64Cu-azacyclopeptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 64Cu-azacyclopeptide.